# A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK

Source: https://onco.cc/trials/nct06994195/  
OnCo record `nct06994195` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Izalontamab brengitecan in ovarian cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) is a phase 3 interventional study registered as NCT06994195 by Sichuan Baili Pharmaceutical Co., Ltd., with 450 participants planned, started 2025-08-04 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06994195
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06994195: https://clinicaltrials.gov/study/NCT06994195

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06994195.json